Evaluation of a tissue-engineered bovine pericardial patch in paediatric patients with congenital cardiac anomalies: Initial experience with the ADAPT-treated CardioCel® patch

William Neethling, G. Strange, Laura Firth, F.E. Smit

    Research output: Contribution to journalArticle

    44 Citations (Scopus)

    Abstract

    OBJECTIVESThis study evaluated the safety, efficacy and clinical performance of the tissue-engineered ADAPT® bovine pericardial patch (ABPP) in paediatric patients with a range of congenital cardiac anomalies.METHODSIn this single-centre, prospective, non-randomized clinical study, paediatric patients underwent surgery for insertion of the ABPP. Primary efficacy measures included early (8) were significantly more likely to die (P = 0.0055, 58% survival compared with 100% survival for less complex surgical repairs). In 19 patients, echocardiographic data were available at 18-36 months with no evidence of device calcification, infection, thromboembolic events or device failure.CONCLUSIONSThis study demonstrates the safety and efficacy of this engineered bovine pericardial patch as a cardiovascular substitute for surgical repair of both simple and more complex congenital cardiac defects. © The Author 2013. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
    Original languageEnglish
    Pages (from-to)698-702
    JournalInteractive Cardiovascular and Thoracic Surgery
    Volume17
    Issue number4
    DOIs
    Publication statusPublished - 2013

    Fingerprint Dive into the research topics of 'Evaluation of a tissue-engineered bovine pericardial patch in paediatric patients with congenital cardiac anomalies: Initial experience with the ADAPT-treated CardioCel® patch'. Together they form a unique fingerprint.

    Cite this